Dapu Biotech develops microfluidic in vitro diagnostic platforms and is building a digital PCR system called the Nebula Digital PCR. Its digital PCR system aims to digitize traditional medical test results for drug guidance and treatment prognosis. The company owns multiple self‑developed instrument platforms, a large biochip manufacturing capability, and integrated instrument and reagent systems. Dapu focuses on droplet microfluidic technology as the core of its diagnostic products. Recently the company completed a RMB 100M‑level B round to support commercialization. Proceeds will be used to commercialize multiple droplet microfluidic platforms globally and to build a leading life‑science instrument tools platform.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2024